Suchergebnisse - "Murakami, Shuji"

PubPharm (180)

1

A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402 : CARNAVAL)

enthalten in: Japanese journal of clinical oncology | 2024

von Nogami, N. | Kubo, T. | Bessho, A. | +15

2

Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis

enthalten in: Cancer medicine | 2024

von Murakami, S. | Shinada, K. | Otsutsumi, Y. | +8

3

Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer : TORG1937 (DATE Study)

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Nakamichi, S. | Kubota, K. | Misumi, T. | +17

4

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

enthalten in: JTO clinical and research reports | 2024

von Vansteenkiste, J. | Naidoo, J. | Faivre-Finn, C. | +13

5

Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma"

enthalten in: Thoracic cancer | 2024

von Shigeta, N. | Yokose, T. | Murakami, S. | +10

6

Artemis : A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas

enthalten in: Clinical lung cancer | 2024

von Okuma, Y. | Nomura, S. | Sakakibara-Konishi, J. | +9

7

Will perioperative pembrolizumab treatment change perioperative treatment strategies for resectable non-small cell lung cancer?

enthalten in: Translational lung cancer research | 2024

von Murakami, S.

CommentOn: N Engl J Med. 2023 Aug 10;389(6):491-503. - PMID 37272513

8

Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab : Results from the Small Cell Lung Cancer Cohort

enthalten in: Cancer research communications | 2024

von Nishio, M. | Murakami, S. | Kawakami, H. | +17

9

Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer : study protocol for ABRAID study (WJOG11919L)

enthalten in: Therapeutic advances in medical oncology | 2024

von Ozawa, Y. | Koh, Y. | Hase, T. | +7

10

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations : The UNICORN Phase 2 Nonrandomized Clinical Trial

enthalten in: JAMA oncology | 2024

von Okuma, Y. | Kubota, K. | Shimokawa, M. | +9

CommentOn: JAMA Oncol. 2024 Jan 1;10(1):52-53. - PMID 37991771

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[18]